EUVIMEDSkopri EUVIMED
Scoping ReviewOpen access · CC BY-NC-ND 4.0

Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review

Lasse Alajärvi iD, Mirella Miettinen iD, Johanna Timonen

Basic & Clinical Pharmacology & Toxicology · 2026-06 · 138 (6)

DOI: 10.1111/bcpt.70243 ↗

At a glance

Scoping Review in Basic & Clinical Pharmacology & Toxicology, published online on 2026-05-10. Written by Lasse Alajärvi and 2 co-authors. Institution: School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. Major MEDLINE topics: Environment, Drug Costs, Reimbursement Mechanisms. 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Kela.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Environmental impacts of medicines are increasingly recognised but rarely embedded in their pricing and reimbursement (P&R) and related assessments. This scoping review mapped how environmental aspects, including antimicrobial resistance (AMR) stewardship, are or could be considered in P&R of medicines and identified challenges for their implementation. Electronic searches from PubMed, Scopus, Web of Science, Edilex, HeinOnline, Westlaw, Google Scholar and official agencies' websites were conducted. Eligible items covered developed country settings and described existing or proposed integration of environmental aspects into medicine pricing or reimbursement. Of 4476 publications, 21 were included. The publications were from 2013 to 2023, most of them addressing ecotoxicological and climate impacts. Six types of means to embed environmental aspects into P&R were identified: health technology assessment (HTA) integration, reimbursement criteria, pricing criteria, environmental classification, regulation and delinkage models. Most proposals were conceptual, whereas implemented or piloted examples focused on AMR‐oriented means. Reported challenges for implementation included challenges regarding data availability, comparability and verification; valuation and methodological integration; incentive design and cost distribution; and equity and political feasibility. Environmental aspects are not yet routine in medicine P&R assessments due to a lack of standardised, verifiable product‐level data, appraisal methods and equity‐sensitive policy design.

Subjects

MeSH terms (MEDLINE)

EnvironmentDrug CostsReimbursement MechanismsHumansTechnology Assessment, BiomedicalCosts and Cost Analysis

Author keywords

environmentmedicinepolicypricereimbursement

Authors and institutions

  • School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Law School, Faculty of Social Sciences and Business Studies, University of Eastern Finland, Kuopio, Finland.

ORCID profiles: Lasse Alajärvi, Mirella Miettinen

Funding

  • Kela

Cite

APA

Alajärvi, L., Miettinen, M., & Timonen, J. (2026). Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review. Basic & Clinical Pharmacology & Toxicology, 138(6). https://doi.org/10.1111/bcpt.70243

Vancouver

Alajärvi L, Miettinen M, Timonen J. Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review. Basic & Clinical Pharmacology & Toxicology. 2026;138(6). doi:10.1111/bcpt.70243

BibTeX
@article{Alajrvi2026,
  author = {Alajärvi, Lasse and Miettinen, Mirella and Timonen, Johanna},
  title = {Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  volume = {138},
  number = {6},
  doi = {10.1111/bcpt.70243}
}
Start for free →